MARLBOROUGH, Mass., May 8, 2020 /PRNewswire/ -- Today, Boston Scientific (NYSE: BSX) announced positive 12-month results from the PINNACLE FLX clinical trial assessing the safety and efficacy of the ...

As physicians and patients await news from the Centers for Medicare & Medicaid Services (CMS) regarding coverage for percutaneous left atrial appendage (LAA) closure, a new analysis suggests that it ...

In a population largely consisting of patients with nonvalvular A-fib who have contraindications to warfarin therapy, implantation of the Watchman left atrial appendage (LAA) closure device appears ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Rates of patency and device-related thrombus were ...

WASHINGTON, DC — Quality-of-life scores were "modestly" but significantly better at one year in patients with atrial fibrillation (AF) if they received the Watchman (AtriTech/Boston Scientific) device ...

New stroke risk reduction therapy with thromboresistant coating is designed to advance procedural performance and safety MARLBOROUGH, Mass., Sept. 6, 2023 /PRNewswire/ -- Boston Scientific Corporation ...

HOUSTON, TX--(Marketwired - Jan 30, 2017) - Memorial City Cardiology Associates offers the WATCHMAN™ Left Atrial Appendage Closure Device Procedure, a breakthrough alternative to blood thinners in ...

SWISS-APERO is the first randomized clinical trial comparing Amulet with the new generation Watchman FLX device in terms of residual left atrial appendage (LAA) patency after percutaneous LAA closure ...

Boston Scientific Corp. and Abbott Laboratories continue to parry over clinical trials comparing the latter’s Amplatzer Amulet with Boston Scientific’s Watchman in sealing the heart’s left atrial ...

Boston Scientific’s Watchman left atrial appendage (LAA) closure device to prevent stroke resulted in significantly less bleeding after an ablation procedure than taking blood thinners, according to a ...

Cardiology is on the brink of making a big mistake. Our embrace of percutaneous closure of the left atrial appendage as a means of reducing stroke in patients with nonvalvular atrial fibrillation (AF) ...